Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Rhea-AI Summary

Annovis Bio (NYSE: ANVS) announced a registered direct offering of 1,670,732 shares of common stock at $2.05 per share (closing price on Oct 24, 2025).

The offering is expected to close on or about October 28, 2025, with aggregate gross proceeds of approximately $3.4 million before placement agent fees and expenses. Michael Hoffman (board chair) and CEO Dr. Maria Maccecchini are participating in the purchase.

H.C. Wainwright & Co. is the exclusive placement agent. Net proceeds are intended for working capital and general corporate purposes. Securities are offered under a Form S-3 shelf registration (No. 333-276814) declared effective Feb 12, 2024.

Positive

• Gross proceeds of approximately $3.4 million
• Insiders (chair and CEO) participating in the purchase

Negative

• Issuance of 1,670,732 shares may cause shareholder dilution
• Net proceeds reduced by placement agent fees and offering expenses

Insights

Equity Capital Markets Analyst

Capital raise of $3.4 million via at‑the‑market registered direct offering; insiders are participating.

The company, Annovis, has agreed to sell 1,670,732 shares at $2.05 per share under its Form S-3 shelf, producing approximately $3.4 million gross before fees. The stated use of proceeds is working capital and general corporate purposes, and the offering closing is expected on or about Oct 28, 2025.

This transaction supplies near‑term liquidity while increasing share count; insider purchases by the Chairman and CEO partially offset typical negative signaling from dilution but do not remove it. Key dependencies include the successful closing and net proceeds after placement agent fees; monitor the filed prospectus supplement for exact fees, share count impact, and any changes to use of proceeds within the next week.

MALVERN, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements, with the participation of Michael Hoffman, the Chairman of the Company’s board of directors, and Dr. Maria Maccecchini, the Company’s Chief Executive Officer, for the purchase of an aggregate of 1,670,732 shares of its common stock at a purchase price of $2.05 per share, which was the closing price of the common stock on NYSE on October 24, 2025, in a registered direct offering. The closing of the offering is expected to occur on or about October 28, 2025, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering are expected to be approximately $3.4 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering toward working capital and general corporate purposes.

The securities described above are being offered and sold by the Company pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-276814), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. The offering is being made only by means of a prospectus supplement that forms a part of the registration statement. A prospectus supplement and an accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
  
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the consummation of the offering, the satisfaction of closing conditions and the use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

What did Annovis (ANVS) announce on October 27, 2025?

Annovis announced a registered direct offering of 1,670,732 shares at $2.05 per share.

How much gross capital will Annovis (ANVS) raise from the offering?

The offering is expected to generate approximately $3.4 million in gross proceeds before fees and expenses.

When is the Annovis (ANVS) offering expected to close?

The closing is expected to occur on or about October 28, 2025, subject to customary closing conditions.

Who is participating in the Annovis (ANVS) registered direct offering?

Michael Hoffman, the company chair, and Dr. Maria Maccecchini, the CEO, are participating buyers.

What will Annovis (ANVS) use the offering proceeds for?

The company intends to use net proceeds for working capital and general corporate purposes.

Who is the placement agent for the Annovis (ANVS) offering?

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.